The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach
Authors:
- Johannes LevinJLJohannes Levin
- The PROMESA study groupTGThe PROMESA study group
- Florian KrismerFKFlorian Krismer
- 25 January 2016
- journal article
- research article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 123 (4) , 439-445
Abstract
Formation of toxic α-synuclein oligomers appears to be a key underlying pathological mechanism of synucleinopathies such as Parkinson’s disease or multiple system atrophy (MSA). Given that Epigallocatechin-gallate has been shown to inhibit α-synuclein aggregation, it might represent a causal treatment option. Therefore, we set out to evaluate the safety, tolerability and a potential disease-modifying effect of Epigallocatechin-gallate in patients with MSA after 48 weeks of treatment. Power calculation was performed on existing natural history data on the progression of the Unified MSA Rating Scale as primary readout parameter. To assess the efficacy of Epigallocatechin-gallate versus placebo regarding the reduction of disease progression measured during the study period (80 % power, 5 % p level, 50 % effect size) 36 patients per group are needed. Considering a drop-out rate of 20 % a total of 86 patients will be recruited in this multicentre study. These data provide a solid rationale to investigate whether supplementation of Epigallocatechin-gallate can delay the progression of the MSA-related disability.Keywords
Funding Information
- ParkinsonFonds Deutschland gGmbH
- Deutsche Parkinson Vereinigung
- Deutsche Stiftung Neurologie
- Arthur Arnstein-Stiftung Berlin
- Lüneburg-Stiftung für Parkinsonforschung
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Standort München
- Bischof Dr Karl Golser Stiftung
This publication has 33 references indexed in Scilit:
- Natural history of multiple system atrophy in the USA: a prospective cohort studyThe Lancet Neurology, 2015
- Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophyMolecular Neurodegeneration, 2015
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s diseaseActa Neuropathologica, 2013
- Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?EPMA Journal, 2013
- Different Iron-Deposition Patterns of Multiple System Atrophy with Predominant Parkinsonism and Idiopathetic Parkinson Diseases Demonstrated by Phase-Corrected Susceptibility-Weighted ImagingAmerican Journal of Neuroradiology, 2011
- Voxel‐Based Morphometry and Voxel‐Based Relaxometry in Parkinsonian Variant of Multiple System AtrophyJournal of Neuroimaging, 2010
- Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structuresNeuroImage, 2010
- Second consensus statement on the diagnosis of multiple system atrophyNeurology, 2008
- Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28Annals of the New York Academy of Sciences, 2004
- Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic ChineseJournal of the Neurological Sciences, 2003